SNVL-31 / Immorta Bio - LARVOL DELTA

Immorta Bio to Present SenoVax Cancer Senolytic Immunotherapy Preclinical Data at American Association of Immunologists Meeting (PRNewswire) - "The Company has shown that its lead senolytic immunotherapy product, SenoVax, is capable of destroying lung, breast, pancreatic and brain cancers, as well as melanoma in animal models....Additionally, the Company recently demonstrated that natural killer cell activation as a result of SenoVax therapy also plays a role in stimulation of cancer destruction."

Preclinical • Brain Cancer • Breast Cancer • Lung Cancer • Melanoma • Pancreatic Cancer

Cancer regression by induction of immunity to senescent cells (IMMUNOLOGY 2025) - "Fibroblasts were rendered senescent using doxorubicin and confirmed by expression of p16, beta-galactosidase, and HMGB1. Tumor regressions were associated with immunological cell infiltration and reduction of the SASP protein IL-6 and augmentation of the natural killer cell-promoting cytokine IL-12. These data support filed IND 30745 representing a proposed clinical trial for SenoVax in lung cancer.Keywords: Animals Human; Cells Dendritic Cells; Processes Antigen Presentation/Processing Cell Activation"

IO biomarker • Brain Cancer • Breast Cancer • CNS Tumor • Glioma • Lung Cancer • Melanoma • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor • CDKN1A • HMGB1 • IL12A • IL6

Senescent Cell Removal Unleashes Natural Killer Cells Shown to Fight Cancer and Viruses in Animal Models (PRNewswire) - "Immorta Bio Inc...announced today results of laboratory experiments, covered in newly filed patent # 63/789,097 entitled 'Augmentation of Natural Killer Cell Number and Activity by Senolytic Therapies', showing that reducing the number of aged cells known as 'senescent cells' result in a potent increase in numbers and activity of natural killer (NK) cells....Our preliminary data suggests that reducing senescent cell burden, either with conventional senolytics such as dasatinib+quercetin combinations, or using our proprietary SenoVax senolytic immunotherapy significantly enhances numbers and activity of NK cells, which may reduce the probability of cancer and viral infections....The filed patent application covers these newly discovered biological mechanisms, including the SenoVax 'teaching' NK cells to kill cancers, an activity that can be transferred from one animal to another."

Patent • Preclinical • Lung Cancer

Immorta Bio Presents SenoVax Mediated Tumor Remission Data at International Biotechnology Conference (PRNewswire) - "Immorta Bio Inc...announced today that its Chairman and CEO, Dr. Boris Reznik, presented the latest findings from its SenoVax Program at the LSX Investival Showcase on March 11th at the Miami Beach Convention Centre....The presentation disclosed advancements in the Company's oncology pipeline, highlighting animal studies showing the regression of brain, lung, skin, pancreas, and breast cancers by SenoVax, the Company's lead product. Additionally, cellular mechanisms by which this 'longevity therapeutic' targets a broad range of cancers were discussed....By amplifying the body's natural immunological activities to kill senescent cells, SenoVax induces regression of tumors."

Preclinical • Brain Cancer • Breast Cancer • Lung Cancer • Pancreatic Cancer • Skin Cancer

SenoVax First-in-Class Senolytic Product to be Presented at Society for Immunotherapy of Cancer Symposium (PRNewswire) - "Immorta Bio Inc...announced today acceptance of its poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) Spring Scientific, Cellular Therapy for Solid Tumors in San Diego, CA, on March 12-13, 2025....We plan to present data demonstrating regression of cancers in animal models of glioma, lung, breast, and pancreatic cancers using our SenoVax approach..."

Preclinical • Breast Cancer • Glioma • Lung Cancer • Pancreatic Cancer

Immorta Bio Advances Lung Cancer Immunotherapy with Peer-Reviewed Animal Data on Senolytic Vaccine (PRNewswire) - "Immorta Bio Inc...has announced the publication of its pioneering research results in the Journal of Stem Cell Research & Therapeutics. The study introduces a novel senolytic immunotherapy, SenoVax, which demonstrated promising results in enhancing anti-tumor immune responses in mice bearing syngeneic Lewis Lung Cancer (LLC) tumors....Immorta Bio has filed an Investigational New Drug (IND) application for SenoVax and anticipates initiating clinical trials in the coming months."

New trial • Preclinical • Lung Cancer • Oncology • Solid Tumor

Immorta Bio’s SenoVax Reduces Growth and Stops Metastasis of Aggressive Breast Cancer Using its First-In-Class Immune Stimulatory Therapy (PRNewswire) - "Immorta Bio Inc...announced today successful treatment of aggressive breast cancer in animal models using its SenoVax senolytic immunotherapy. In a series of experiments, scientists at Immorta Bio found that administration of SenoVax resulted in shrinkage of existing breast cancers, as well as reduction of metastasis."

Preclinical • Breast Cancer

SenoVax Breakthrough: Cancer Immunotherapy Preserves Immune Function Post-Chemotherapy in Animal Models (PRNewswire) - "Immorta Bio Inc...announced today new animal study data demonstrating that its SenoVax cancer immunotherapy not only reduces tumor growth but also enhances white blood cell production following chemotherapy. These findings highlight SenoVax's potential to address the multi-billion-dollar market currently served by drugs like Filgrastim, which are used to treat chemotherapy-induced neutropenia...This therapy has...proposed Phase I/IIa study in non-small cell lung cancer patients....In addition to its anti-cancer properties, SenoVax has shown the ability to enhance both endogenous and exogenous stem cell activity by clearing the body of senescent cells. This has been demonstrated in two murine models of liver failure and is covered in patent application #63/660973..."

New P1/2 trial • Patent • Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Immorta Bio Files Investigational New Drug Application for First in Class Senolytic Immunotherapy SenoVax for Treatment of Advanced Lung Cancer (PRNewswire) - "Immorta Bio Inc...announced the filing of an Investigational New Drug (IND) application with the Food and Drug Administration (FDA). The IND, which was granted #30745, is to initiate a clinical trial to evaluate safety, immunogenicity, and efficacy signals of SenoVax in patients with advanced non-small cell lung cancer. The trial will recruit patients who have failed standard therapies and will comprise of three patient groups receiving increasing doses of SenoVax."

IND • New trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Immorta Bio Reports Successful Inhibition of Lung Cancer Growth by Senolytic Immunotherapy Product SenoVax (PRNewswire) - "Immorta Bio Inc...announced today positive preclinical findings utilizing its senescent cell-killing immunotherapeutic product SenoVax in a model of non-small cell lung cancer. The results, which are reported in a filed patent, demonstrate successful induction of immunity to senescent cells surrounding lung cancer cells, and reproducible regression of established tumors. The SenoVax immunotherapy was administered in absence of other cancer killing therapeutics....The Company is currently in the late phase of preclinical development and plans to file an Investigational New Drug (IND) application with the FDA shortly to initiate treatment of advanced lung cancer patients."

Preclinical • Lung Cancer • Oncology • Solid Tumor